Sterling offers tailored solutions delivering service, quality, speed and value through world class capabilities and facilities suitable for every scale across the whole drug development lifecycle, meaning they are able to go from proof of concept to commercial manufacture on one site.
Though a relatively new name on the scene (Sterling was launched in 2016 following a management buy-out) the company has a proud pedigree in Pharma API manufacture dating back to 1969, when the original Sterling Drug API facility was established in Dudley, Northumberland. The company's roots in Britest are almost as deep, and can be traced back through Shasun Pharma Solutions to Rhone Poulenc / Rhodia's involvement in the original BRITEST collaborative project. Britest has been used as a powerful trouble shooting tool at Dudley, and has also proven its worth as a means of working together with customers in supply chains to turn shared processing problems into joint benefits. Sterling has been an active participant in the Britest innovation programme, amongst other things helping to develop what is now known as the Britest Scale-up Risk Assessment.Methodology, and has also been prominent in using the ChemDecide decision support software tool to support route selection.